Pharmacology of epigenetics in brain disorders
- 26 January 2010
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 159 (2) , 285-303
Abstract
Epigenetics is a rapidly growing field and holds great promise for a range of human diseases, including brain disorders such as Rett syndrome, anxiety and depressive disorders, schizophrenia, Alzheimer disease and Huntington disease. This review is concerned with the pharmacology of epigenetics to treat disorders of the epigenome whether induced developmentally or manifested/acquired later in life. In particular, we will focus on brain disorders and their treatment by drugs that modify the epigenome. While the use of DNA methyl transferase inhibitors and histone deacetylase inhibitors inin vitroandin vivomodels have demonstrated improvements in disease‐related deficits, clinical trials in humans have been less promising. We will address recent advances in our understanding of the complexity of the epigenome with its many molecular players, and discuss evidence for a compromised epigenome in the context of an ageing or diseased brain. We will also draw on examples of species differences that may exist between humans and model systems, emphasizing the need for more robust pre‐clinical testing. Finally, we will discuss fundamental issues to be considered in study design when targeting the epigenome.Keywords
This publication has 272 references indexed in Scilit:
- A MicroRNA gene is hosted in an intron of a schizophrenia-susceptibility geneSchizophrenia Research, 2009
- Endophenotypes in schizophrenia: A selective reviewSchizophrenia Research, 2009
- High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer DiseaseJAMA, 2008
- Epigenomic Profiling Reveals DNA-Methylation Changes Associated with Major PsychosisThe American Journal of Human Genetics, 2008
- Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disordersCurrent Opinion in Pharmacology, 2008
- Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: Analysis of the National Brain Databank microarray collectionSchizophrenia Research, 2008
- Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicityNeuroscience, 2007
- Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studiesMedicinal Research Reviews, 2005
- Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA TargetsCell, 2005
- The Transcriptional Coactivators p300 and CBP Are Histone AcetyltransferasesCell, 1996